Gelteq (GELS) Competitors $0.93 +0.05 (+5.94%) As of 04/17/2025 03:34 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOwnershipSEC FilingsTrendsBuy This Stock GELS vs. ELYM, SCYX, SPRO, HOWL, ESLA, FBLG, LTRN, AKTX, COEP, and RNTXShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Eliem Therapeutics (ELYM), SCYNEXIS (SCYX), Spero Therapeutics (SPRO), Werewolf Therapeutics (HOWL), Estrella Immunopharma (ESLA), FibroBiologics (FBLG), Lantern Pharma (LTRN), Akari Therapeutics (AKTX), Coeptis Therapeutics (COEP), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Eliem Therapeutics SCYNEXIS Spero Therapeutics Werewolf Therapeutics Estrella Immunopharma FibroBiologics Lantern Pharma Akari Therapeutics Coeptis Therapeutics Rein Therapeutics Gelteq (NASDAQ:GELS) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking. Which has better valuation & earnings, GELS or ELYM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGelteqN/AN/AN/AN/AN/AEliem TherapeuticsN/AN/A-$35.12M-$0.53-2.38 Does the MarketBeat Community prefer GELS or ELYM? Eliem Therapeutics received 9 more outperform votes than Gelteq when rated by MarketBeat users. CompanyUnderperformOutperformGelteqN/AN/AEliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Is GELS or ELYM more profitable? Gelteq's return on equity of 0.00% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GelteqN/A N/A N/A Eliem Therapeutics N/A -47.03%-45.97% Do insiders and institutionals believe in GELS or ELYM? 69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor GELS or ELYM? In the previous week, Gelteq had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Gelteq and 0 mentions for Eliem Therapeutics. Gelteq's average media sentiment score of 0.30 beat Eliem Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the media. Company Overall Sentiment Gelteq Neutral Eliem Therapeutics Neutral SummaryGelteq beats Eliem Therapeutics on 4 of the 7 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.74M$6.46B$5.32B$7.35BDividend YieldN/A3.21%5.47%4.34%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.9597.73Price / CashN/A65.6738.3134.64Price / BookN/A5.936.453.98Net IncomeN/A$143.22M$3.22B$247.81M7 Day Performance12.93%4.28%5.85%3.19%1 Month Performance-5.64%-13.11%-9.58%-7.70%1 Year PerformanceN/A-8.51%11.85%1.49% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$0.93+5.9%N/AN/A$8.74MN/A0.00N/ANews CoverageGap DownELYMEliem TherapeuticsN/A$1.13-10.3%N/A-67.3%$33.62MN/A-2.139SCYXSCYNEXIS0.1948 of 5 stars$0.86+7.1%N/A-37.2%$33.57M$3.75M-1.1660Gap UpSPROSpero Therapeutics4.1026 of 5 stars$0.59+5.3%$5.00+747.6%-46.1%$32.98M$27.40M8.43150High Trading VolumeHOWLWerewolf Therapeutics2.7194 of 5 stars$0.72+14.2%$9.00+1,150.5%-84.4%$32.26M$1.89M-0.4740News CoverageESLAEstrella Immunopharma2.9131 of 5 stars$0.89+1.5%$16.00+1,701.8%-25.8%$32.12MN/A-3.42N/AShort Interest ↓FBLGFibroBiologics1.5392 of 5 stars$0.85+4.3%$13.00+1,429.4%-88.3%$32.08MN/A-2.5010LTRNLantern Pharma1.969 of 5 stars$2.94+14.0%$25.00+750.3%-36.0%$31.71MN/A-1.6520Gap UpAKTXAkari TherapeuticsN/A$1.19+3.5%N/A+3.2%$31.64MN/A0.009Analyst ForecastNews CoverageCOEPCoeptis Therapeutics0.4396 of 5 stars$9.37+0.8%N/A+51.1%$31.53MN/A-1.622Short Interest ↑News CoverageRNTXRein TherapeuticsN/A$1.45+4.3%N/AN/A$31.42MN/A-0.469News CoverageGap Down Related Companies and Tools Related Companies Eliem Therapeutics Competitors SCYNEXIS Competitors Spero Therapeutics Competitors Werewolf Therapeutics Competitors Estrella Immunopharma Competitors FibroBiologics Competitors Lantern Pharma Competitors Akari Therapeutics Competitors Coeptis Therapeutics Competitors Rein Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GELS Stock Free GELS Stock Alerts